Cibus, Inc. (CBUS)
| Market Cap | 86.36M +20.6% |
| Revenue (ttm) | 4.53M +19.5% |
| Net Income | -96.59M |
| EPS | -1.42 |
| Shares Out | 76.43M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 148,902 |
| Open | 1.080 |
| Previous Close | 1.090 |
| Day's Range | 1.016 - 1.140 |
| 52-Week Range | 1.016 - 4.191 |
| Beta | 1.64 |
| Analysts | Buy |
| Price Target | 12.00 (+961.95%) |
| Earnings Date | Nov 12, 2026 |
About CBUS
Cibus, Inc. is an agricultural biotechnology company that develops and licenses gene-edited plant traits. The company's products enable farmers to achieve higher yields and reduce the use of chemicals, such as fungicides, insecticides and fertilizers, and offer sustainable ingredients. it has patented core technology platform, RTDS, a scalable, standardized, end-to-end, semi-automated and high-throughput gene-editing system marketed under the Trait Machine brand name. The company was formerly known as Calyxt, Inc. and changed its name to Cibus,... [Read more]
Financial Performance
In 2025, Cibus's revenue was $3.64 million, a decrease of -14.62% compared to the previous year's $4.26 million. Losses were -$127.09 million, -49.45% less than in 2024.
Financial StatementsAnalyst Summary
According to 3 analysts, the average rating for CBUS stock is "Buy." The 12-month stock price target is $12.0, which is an increase of 961.95% from the latest price.
News
Cibus price target lowered to $9 from $16 at Alliance Global
Alliance Global lowered the firm’s price target on Cibus (CBUS) to $9 from $16 and keeps a Buy rating on the shares following the Q3 report. The company’s crop trait…
Cibus Earnings Call Transcript: Q3 2026
Q3 revenue rose YoY and operating expenses fell, while net loss narrowed; cash is expected to fund operations into early Q1 2027, with near-term capital needed. Bio-fragrance and rice advanced, supporting focused commercialization plans.
Cibus Earnings release: Q3 2026
Cibus released its Q3 2026 earnings on November 12, 2026, summarizing the period's financial results.
Cibus Quarterly report: Q3 2026
Cibus has published its Q3 2026 quarterly earnings report on November 12, 2026.
Cibus Reports Third Quarter Financial Results and Provides Business Update
Rice herbicide-tolerance traits performed well in Latin American field trials and are now being tested by customer Interoc in its own varieties Initiated the manufacturing process for initial two biof...
Cibus to Report Third Quarter 2026 Financial Results on November 12, 2026 After the Market Close and Host Conference Call
SAN DIEGO, Nov. 03, 2026 (GLOBE NEWSWIRE) -- Cibus, Inc. (Nasdaq: CBUS), a technology company that uses biology to produce sustainable ingredients and helps farmers grow more food with fewer inputs, t...
Cibus and Crystal Crop Protection Team Up to Improve India's Mustard Crop
Collaboration pairs Cibus' platform for improving a plant's own genes with Crystal Crop's mustard varieties and its reach across India, with the goal of putting better-performing seed in growers' hand...
Cibus Earnings Call Transcript: Q2 2026
Revenue grew 35% year-over-year, driven by Sustainable Ingredients, while cost discipline reduced operating expenses and net loss. Rice royalty revenue is expected to begin in 2028, with a multi-year ramp to over $200 million annually. Regulatory progress in the EU and Americas supports future launches.
Cibus Earnings release: Q2 2026
Cibus released its Q2 2026 earnings on August 13, 2026, summarizing the period's financial results.
Cibus Quarterly report: Q2 2026
Cibus has published its Q2 2026 quarterly earnings report on August 13, 2026.
Cibus Reports Second Quarter Financial Results and Provides Business Update
Commercialization execution advances in Rice and Sustainable Ingredients United States and European Union now aligned on generally treating crops with no added foreign DNA as conventionally bred Quart...
Cibus to Report Second Quarter 2026 Financial Results on August 13, 2026 After the Market Close and Host Conference Call
SAN DIEGO, July 30, 2026 (GLOBE NEWSWIRE) -- Cibus, Inc. (Nasdaq: CBUS), a technology company that helps farmers grow more food with fewer inputs, today announced that the company will report second q...
Cibus Transcript: Sidoti Small-Cap Virtual Investor Conference
EU regulatory changes now treat gene editing as natural breeding, unlocking major markets and accelerating commercialization. Rapid Trait Development System enables faster, non-GMO crop trait delivery, with rice and fragrance products set to drive revenue growth and profitability by 2028-2029.
Europe Recognizes Nature-Based Plant Improvement, Opening a New Pathway for Cibus
Under new EU rules, crops improved without adding foreign DNA will be treated like conventionally bred crops, validating the approach Cibus has developed for 25 years Under new EU rules, crops improve...
Cibus names Craig Wichner as CEO
Cibus (CBUS) announced key leadership changes pursuant to the company’s previously announced succession planning strategy. As part of this plan, Craig Wichner, a board member since November 2025, has ...
Cibus Names Agricultural Biotechnology Leader Craig Wichner as Chief Executive Officer to Accelerate Growth and Value Creation
SAN DIEGO, June 08, 2026 (GLOBE NEWSWIRE) -- Cibus, Inc. (Nasdaq: CBUS) (the “Company” or “Cibus”), a leading agricultural technology company that develops and licenses plant traits to seed companies,...
Cibus Transcript: AGM 2026
The meeting saw the re-election of all nine directors, approval of executive compensation, and auditor ratification. No additional proposals or pertinent shareholder questions were presented. Final voting results will be filed with the SEC.
Cibus files $200M mixed securities shelf
16:36 EDT Cibus (CBUS) files $200M mixed securities shelf
Cibus Registration statement: Registration filing
Cibus filed a registration statement on May 15, 2026, providing details about a securities offering with the SEC.
Cibus Earnings Call Transcript: Q1 2026
Q1 2026 saw strong commercial progress, cost reductions, and a $37M capital raise, supporting a clear path to 2027 LATAM rice launch and ramping sustainable ingredients revenue. U.S. rice launch is delayed to 2029, but regulatory and partner milestones advance commercialization.
Cibus Earnings release: Q1 2026
Cibus released its Q1 2026 earnings on May 14, 2026, summarizing the period's financial results.
Cibus Quarterly report: Q1 2026
Cibus has published its Q1 2026 quarterly earnings report on May 14, 2026.
Cibus Reports First Quarter Financial Results and Provides Business Update
SAN DIEGO, May 14, 2026 (GLOBE NEWSWIRE) -- Cibus, Inc. (Nasdaq: CBUS) (the "Company"), a leading agricultural technology company that develops and licenses plant traits to seed companies, today annou...
Cibus transfers gene-edited materials for herbicide tolerance in rice to Interoc
Cibus (CBUS) announced the transfer of gene-edited materials for herbicide tolerance in rice to its partner, Interoc. This transition facilitates the commencement by Interoc of testing and production ...
Cibus Announces Transfer of Gene-Edited Herbicide Tolerance Traits in Interoc Rice Seeds for Testing and Production
Represents achievement of strategic milestone for Cibus' anticipated first commercial offering in the South American market Represents achievement of strategic milestone for Cibus' anticipated first c...